VITAMIN D3 RESEARCH - Calcifediol treatment and COVID-19-related outcomes | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic

Accepted manuscript

• PDF
• Split View
• • Article contents
  • Figures & tables
  • Video
  • Audio
  • Supplementary Data
• Cite

  Cite

  Xavier Nogues, Diana Ovejero, Marta Pineda-Moncusí, Roger Bouillon, Dolors Arenas, Julio Pascual, Anna Ribes, Robert Guerri-Fernandez, Judit Villar-Garcia, Abora Rial, Carme Gimenez-Argente, Maria Lourdes Cos, Jaime Rodriguez-Morera, Isabel Campodarve, José Manuel Quesada-Gomez, Natalia Garcia-Giralt, Calcifediol treatment and COVID-19-related outcomes, The Journal of Clinical Endocrinology & Metabolism, 2021;, dgab405, https://doi.org/10.1210/clinem/dgab405

  Close

Abstract

Context

COVID-19 is a major health problem because of saturation of intensive care units (ICU) and mortality. Vitamin D has emerged as a potential treatment able to reduce the disease severity.

Objective

To elucidate the effect of calcifediol [25OHD3] treatment on COVID-19-related outcomes.

Design

Observational cohort study from March to May, 2020.

Setting

Patients admitted to COVID-19 wards of Hospital del Mar, Barcelona, Spain.

Patients

A total of 930 patients with COVID-19 were included. Ninety-two were excluded due to previous calcifediol intake.

Intervention

Of the remaining 838, a total of 447 received calcifediol (532ug on day one plus 266ug on day 3, 7, 15, and 30) whereas 391 were not treated at the time of hospital admission (Intention-to-Treat). Of the latter, 53 patients were treated later during ICU admission and were allocated in the treated group in a second analysis. In healthy subjects, calcifediol is about 3.2-fold more potent on a weight basis than cholecalciferol.

Main Outcome Measures

ICU admission and mortality.

Results

ICU assistance was required by 102 (12.2%) participants. Out of 447 patients treated with calcifediol at admission, 20 (4.5%) required ICU, compared to 82 (21%) out of 391 non-treated (p-value<0.0001). Logistic regression of calcifediol treatment on ICU admission, adjusted by age, gender, linearized 25OHD levels at baseline, and comorbidities showed that treated patients had a reduced risk to require ICU (OR 0.13 [95% CI 0.07;0.23]). Overall mortality was 10%. In the Intention-to-Treat analysis, 21 (4.7%) out of 447 patients treated with calcifediol at admission died compared to 62 patients (15.9%) out of 391 non-treated (p=0.0001). Adjusted results showed a reduced mortality risk with an OR 0.21 [95% CI 0.10; 0.43]). In the second analysis, the obtained OR was 0.52 [95% CI 0.27;0.99].

Conclusions

In patients hospitalized with COVID-19, calcifediol treatment significantly reduced ICU admission and mortality.

This content is only available as a PDF.

Author notes

© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com